A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Public ClinicalTrials.gov record NCT07222917. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.
Study identification
- NCT ID
- NCT07222917
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 222 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2025
- Primary completion
- Dec 9, 2026
- Completion
- Dec 9, 2026
- Last update posted
- Aug 31, 2026
2025 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Surprise | Arizona | 85374 | — |
| Research Site | Hollywood | Florida | 33021 | — |
| Research Site | Port Charlotte | Florida | 33952 | — |
| Research Site | Port Orange | Florida | 32127 | — |
| Research Site | East Point | Georgia | 30344 | — |
| Research Site | Champaign | Illinois | 61822 | — |
| Research Site | Wichita | Kansas | 67214 | — |
| Research Site | Greenville | North Carolina | 27834 | — |
| Research Site | Jacksonville | North Carolina | 28546 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | Columbus | Ohio | 43215 | — |
| Research Site | Media | Pennsylvania | 19063 | — |
| Research Site | East Providence | Rhode Island | 02914 | — |
| Research Site | Arlington | Texas | 76015 | — |
| Research Site | Pasadena | Texas | 77504 | — |
| Research Site | San Antonio | Texas | 78212 | — |
| Research Site | Woodbridge | Virginia | 22192 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07222917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07222917 live on ClinicalTrials.gov.